Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: an AIDS Malignancy Consortium Study (AMC-A03)

Autor:	Thomas M, Atkinson, Joel, Palefsky, Yuelin, Li, Andrew, Webb, J Michael, Berry, Stephen, Goldstone, Rebecca, Levine, Timothy J, Wilkin, Gary, Bucher, David, Cella, Jack E, Burkhalter, Amanda, Watsula-Morley
Rok vydání:	2019
Předmět:	Adult Male medicine.medical_specialty Intraclass correlation Article 03 medical and health sciences 0302 clinical medicine Cronbach's alpha Surveys and Questionnaires Internal medicine Humans Medicine Anal cancer Watchful Waiting Reliability (statistics) Acquired Immunodeficiency Syndrome business.industry 030503 health policy & services Incidence (epidemiology) Public health Public Health Environmental and Occupational Health Discriminant validity Reproducibility of Results Middle Aged Anus Neoplasms medicine.disease Treatment Outcome 030220 oncology & carcinogenesis Quality of Life Female Self Report Squamous Intraepithelial Lesions of the Cervix Outcomes research 0305 other medical science business
Zdroj:	Qual Life Res
ISSN:	1573-2649 0962-9343
Popis:	PURPOSE: The Anal Cancer HSIL Outcomes Research (ANCHOR) trial aims to determine whether treating precancerous anal high-grade squamous intraepithelial lesions (HSIL), versus active surveillance, is effective in reducing anal cancer incidence in HIV-infected individuals. We evaluated the reliability (i.e., internal consistency, test–retest) and between-group stability of a 25-item ANCHOR Health-Related Symptom Index (A-HRSI). METHODS: ANCHOR participants at least 1-month post-randomization to treatment or active surveillance completed the A-HRSI via telephone. Participants were contacted 7–10 days later to complete the A-HRSI and a participant global impression of change (PGIC) item. RESULTS: Participants (n = 100) were enrolled (mean age = 51.4, 79% cisgender-male, 73% African American, 9% Hispanic) from five ANCHOR sites. Cronbach’s α was good for the physical symptoms (0.82) domain and fair for the physical impacts (0.79) and psychological symptoms (0.73) domains. Intraclass correlation coefficients were good for each of respective domains (i.e., 0.80, 0.85, and 0.82). There were no significant differences in PGIC between the treatment (n = 56) and active surveillance (n = 44) groups (F(1,98) = 2.03, p = 0.16). CONCLUSIONS: The A-HRSI is able to reliably assess participant-reported symptoms and impacts of anal HSIL across a 7–10 days of timeframe. Future work will involve the establishment of construct and discriminant validity prior to inclusion in the full ANCHOR trial.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::363e0b50a0ebcafee74ef210214829e0 https://doi.org/10.1007/s11136-018-2089-8 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.